department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Fyarro · pharmadog

pharmadog
drugs
Fyarro

drug

patient view →

sirolimus albumin-bound

Marketedupdated 2mo ago

by Kaken Pharmaceutical Co Ltd

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 19 approved and 113 investigational indications.

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Fyarro

generic

sirolimus

MOA

FK506-binding protein 1A inhibitor

indication

Mesenchymal Tumor

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Nov 22, 2028

~2.4 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (7)

Oct 28, 2040formulationUS 11497737
Jun 29, 2036method-of-use (U-3258)US 10973806
Jun 29, 2036method-of-use (U-4042)US 12133844
Mar 5, 2036formulationUS 10705070
Mar 5, 2036formulationUS 12061183
Apr 15, 2030formulationUS 102068873.8y
Feb 14, 2029formulationUS 89117862.6y

FDA exclusivities (2)

Mar 22, 2029ODE-391Orphan Drug (7y)2.7y
Nov 22, 2028ODE-386Orphan Drug (7y)2.4y

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 3

drugsirolimus18 co-mentions · 6 sources
tagAdCom10 co-mentions · 6 sources
tagPMA Approval10 co-mentions · 6 sources

Trials studying sirolimus albumin-bound

N/AMOTIV BTK Randomized Controlled Trialactive not recruitingn=292
phase1131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)recruitingn=24
N/ASafety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesionsrecruitingn=150
phase2TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancerrecruitingn=4,200
phase3Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumorsrecruitingn=298
—S-FLEX Netherlands Registry: Prospective Evaluation of the Supraflex Family Sirolimus-eluting Coronary Stent Systemrecruitingn=10,000
phase4Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Settingnot yet recruitingn=20
N/ANon-inferiority Clinical Trial to Compare the Safety and Performance of MeRes100 Sirolimus-eluting BioResorbable Vascular Scaffold System Versus Contemporary DES Platforms in Patients With de Novo Coronary Artery Lesionswithdrawn

more trials →